Gufic Biosciences Limited — Q3 FY26 earnings call

Call held 16 Feb 2026

Management summary

Gufic Biosciences reported a largely flat Q3 FY26 revenue with a slight EBITDA margin compression, primarily due to strategic adjustments in debtor management and domestic branded business. However, strong growth in international business and the Botulinum Toxin segment, coupled with the ongoing ramp-up of the Indore plant and successful EU audit, provide positive momentum for future quarters. The company aims for a minimum of 15% growth in FY27.

Highlights

  • Q3 FY26 Revenue was INR 231.1 crores, showing a slight QoQ increase from INR 230.4 crores.

  • Profit After Tax (PAT) for Q3 FY26 was INR 15.6 crores, up 4.7% QoQ from INR 14.9 crores, with PAT margin improving to 6.75%.

  • International business demonstrated strong growth, increasing by INR 60-70 crores from a base of INR 120 crores.

  • The Botulinum Toxin segment achieved a 23% market share in India and grew by 20-25%.

  • The Indore plant's output has significantly ramped up from INR 25-26 crores to INR 38-42 crores, with EU audit completed in December 2025.

  • Debtors are targeted to be brought down to sub INR 300 crores from INR 320 crores.

Concerns

  • EBITDA for Q3 FY26 was INR 37.1 crores, a 2.1% QoQ decline from INR 37.9 crores, leading to a margin compression from 16.45% to 16.05%.

  • The company took a hit of INR 14-16 crores in Q3 due to efforts to control debtors and revamp operations, with an additional INR 3-5 crores hit expected in Q4.

  • Domestic branded business, particularly Sparsh and Critical Care, experienced a 'stagnant year' with an approximate INR 22 crores correction due to a strategic shift from direct hospital billing to stockist model.

Key financials

  1. Revenue ₹231.1 Cr +0.3%QoQ
  2. EBITDA ₹37.1 Cr -2.1%QoQ
  3. EBITDA Margin 16.1%
  4. PBT ₹21.1 Cr +2.9%QoQ
  5. PBT Margin 9.1%
  6. PAT ₹15.6 Cr +4.7%QoQ
  7. PAT Margin 6.8%

What they filed

Q1 FY27: revenue up 15.0%, net profit up 83.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue204 208 205 227 230 +13%231 +11%252 +23%261 +15%
EBITDA39 34 27 32 36 −8%36 +6%46 +70%47 +47%
Net profit22 19 8 12 15 −32%16 −16%21 +163%22 +83%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • International Business (Formulations)
    ₹60 Cr Growth from Base₹120 Cr Base Revenue
  • Botulinum Toxin
    23% Market Share₹25 Cr Revenue20% Growth
  • Infertility
    16% Growth
  • Aesthetics/Ayurveda/Mass Marketing
    12% Growth

Order book

high confidence

Total value

₹150 Cr

as of 2025-12-31 range

Execution

currently a 90-day window, target 60-day window

Management aims to reduce the order book window from 90 days to 60 days to improve efficiency and working capital.

Source: Q&A

Capital allocation

high confidence
  • Debt Gross ₹375 Cr
    See, presently, we have only 2 types of loans. One is term loan which has been taken for Indore plant, and one is working capital requirement. Including both the loans, I can say, today, it is around INR375 crores, and it may remain at the same level at least for '27.

Guidance & targets

Revenue Growth

  • FY27 Revenue Growth Revenue Growth · FY27 · High confidence minimum 15%
    But like I said, it's a mandate given by the CFO and myself to the team that whatever has to be done, we want to migrate to that, stockiest billing as soon as possible, and don't go for that, I would say, stretched working capital. So I don't think the impact of that what you call Sparsh and Critical Care would stretch on beyond this year. So 15% bare minimum is what we target for '27.

    — Pranav Choksi

Regulatory Approval

  • Indore EU Audit Certificate Regulatory Approval · Q4 FY26 · High confidence by March or April
    So we hope, like I mentioned that the certificate should come by March or April.

    — Pranav Choksi

Market Access

  • Uplift from Indore for EU markets Market Access · Q2-Q3 FY27 · Medium confidence Q2, max Q3
    we look at Q2, max Q3 for uplift of EU markets at least from Indore.

    — Pranav Choksi

Indore Plant Output

  • Indore Output Indore Plant Output · near term · High confidence close to INR 40-42 crores

    From INR 36-38 crores today

    that has at least gone to around INR36 crores to INR38 crores. So that's a positive sign, and we hope that should go to close to INR40 crores, INR42 crores.

    — Pranav Choksi

Working Capital

  • Debtors Working Capital · near term · High confidence sub INR 300 crores

    From around INR 320 crores today

    we want to bring the debtors sub INR300 crores.

    — Pranav Choksi

  • Average Receivable Days Working Capital · FY26 · High confidence around 120 days

    From around 140 days today

    Last year, our average days was around 140 days. And in '26, we are expecting it should come down to around 120 days.

    — Devkinandan Roonghta

Cost Management

  • Employee Benefit Expenses Cost Management · FY27 · Medium confidence INR 160-175 crores
    Next year, another package, you can see a hike of around 7% annual increment. The number is, now, see, it's only annual increment which has to be given to the employees. So it may touch from INR160 crores to INR175 crores.

    — Devkinandan Roonghta

Capacity Utilization

  • Indore Utilization Capacity Utilization · Q4 FY26-FY27 · Medium confidence 50%
    By end of you can expect in Q4 of '25, FY '26-'27, the utilization will touch to 50%, but not at the average of the full year.

    — Devkinandan Roonghta

Profitability

  • EBITDA Margin Profitability · after 2-3 years · Medium confidence 19%

    From 16% today

    After 2, 3 years, when the capacity utilization of Indore will rise more than 50%, we expect the margin again, EBITDA margin will rise from 16% to 19%.

    — Devkinandan Roonghta

  • EBITDA Margin Profitability · when utilization > 75% · Low confidence 20-21%

    From 19% today

    And once the utilization reached more than 75%, then EBITDA margin may touch between 20%, 21%.

    — Devkinandan Roonghta

Debt

  • Gross Debt Debt · till March '27 · High confidence INR 375 crores
    it is around INR375 crores, and it may remain at the same level at least for '27.

    — Devkinandan Roonghta

Expenses

  • Depreciation & Interest Expenses · next year · High confidence INR 35-36 crores
    It is around today, it is around INR35 crores to INR36 crores. I think it will going to remain in the same level in next year also.

    — Devkinandan Roonghta

Product Launch

  • Fillers Product Launch Product Launch · Q1 FY27 · High confidence June, July
    So with that coming in, we should be hoping to get that product launched by June, July.

    — Pranav Choksi

R&D Pipeline

  • Selvax Cancer Vaccine R&D Pipeline · long term · Low confidence 5-6 years
    It will still take 5, 6 years.

    — Pranav Choksi

What to watch in Q4 FY26

Indore EU Audit Certificate Status

March or April 2026
Current EU audit completed in December 2025
Target Certificate received

Why it matters

EU GMP approval is crucial for unlocking export potential from the Indore facility to regulated markets.

So we hope, like I mentioned that the certificate should come by March or April.

Risks & concerns

  • Revenue impact from debtor control and operational revamp

    high

    The company took a hit of INR 14-16 crores in Q3 and expects INR 3-5 crores in Q4 due to efforts to control debtors and shift to a stockist model for Sparsh and Critical Care.

    Management acknowledged

  • Working capital stretch due to long payment cycles

    medium

    Direct hospital billing led to working capital getting affected in long cycles, prompting a strategic shift to stockist model.

    Management acknowledged

  • Delays due to regulatory approvals and validation batches

    medium

    Regulations take time, and validation batches are still ongoing, which can affect product launches and ramp-up timelines.

    Management acknowledged

  • Uncertainty in GLP-1 landscape

    low

    Management noted that the GLP-1 landscape is evolving and its future impact is unknown.

    Management acknowledged

Q&A highlights

6 direct
Flat Q-on-Q growth despite positive developments Partial
But the numbers are saying otherwise that there are many segments, many interesting developments going on, but we are seeing growth of only 11% to 12% on a year-on-year basis and even quarter-on-quarter, it's flat. So any colour that is this due to some Critic Care price erosion? Or what is the scenario here?

Analyst questions the flat QoQ growth despite management's positive commentary on various segments, prompting management to explain the impact of strategic shifts and debtor control.

Asked by Nitya Shah

Outlook for FY27 growth and tangible payoff from capacity expansion Direct
So what is your outlook for FY '27? Say, that once you move onwards from, say, 30% capacity utilization, are we looking to see a 20% plus kind of growth number in FY '27? Because it's been a very large capacity expansion. So when will we start seeing like a tangible payoff? I understand after the debtors have been sorted out. But when are we seeing a larger growth come in, in FY '27? What is your expectation on that?

Analyst probes for specific growth targets for the next fiscal year, seeking clarity on when the benefits of large capacity expansion will materialize.

Asked by Nitya Shah

Uptick in CMO business and Indore ramp-up Direct
We were also expecting some uptick in our CMO business this quarter and going towards next quarter. So how is that panning out to be?

Analyst asks for an update on the CMO business and Indore's contribution, which was expected to show significant growth.

Asked by Adityapal

Increase in employee benefit expenses Direct
And in terms of the cost base, right, so employee benefit expenses has been going up quarter-on-quarter for the last 4 quarters. Today, it's at INR40-odd crores. How much of this would be the -- because of the onetime labour cost, and how much would it be due to organic?

Analyst seeks clarification on the rising employee costs, differentiating between one-time and organic increases.

Asked by Adityapal

Conservative FY27 growth target of 15% Partial
So where -- what is keeping us on the fence to say that not 20%, but 15%? Is there anything that we should be aware of?

Analyst challenges management's conservative FY27 growth guidance, given multiple positive developments like Indore ramp-up and EU GMP.

Asked by Adityapal

Botulinum Toxin business growth, capacity, and export potential Direct
What is the current size of that business? And how is it -- compared to the last couple of years, how has it grown? And with the team expanding, how do you see the growth in this segment for the next, say, maybe 2, 3 years? And also, if you could just highlight what is our capacity here in terms of sales potential? And if there is any potential in terms of exports for this product?

Analyst asks for a comprehensive overview of the Botulinum Toxin business, including market size, growth, capacity, and export potential, highlighting its strategic importance.

Asked by Vishal Mehta

Margin trajectory with Indore ramp-up Direct
What is it that we look at in terms of margin trajectory with Indore ramping up? How do you see that panning out over the next 2, 3 years?

Analyst seeks long-term guidance on EBITDA margin expansion as the Indore plant's utilization increases.

Asked by Vishal Mehta

Impact of Sparsh/Critical Care strategy change on working capital and debtor days Direct
I just want to understand that when we started the direct-to-hospital approach, we thought we would get some kind of understanding of the patterns, etc. And now we are rolling it back. So what exactly are we what issues did we face that we are trying to roll it back?

Analyst questions the rationale behind rolling back the direct-to-hospital strategy, seeking insights into the challenges faced and the impact on working capital.

Asked by Bhavya Sonawala

3 min read 6 chapters

Detailed narrative

Q3 FY26 Financial Performance and Strategic Adjustments

Gufic Biosciences reported a Q3 FY26 turnover of INR 231.1 crores, a marginal increase from INR 230.4 crores in Q2 FY26. EBITDA saw a slight decline to INR 37.1 crores from INR 37.9 crores QoQ, resulting in margin compression to 16.05%. Profit After Tax, however, improved by 4.7% QoQ to INR 15.6 crores. The company consciously took a hit of INR 14-16 crores in Q3, and expects INR 3-5 crores in Q4, as part of a strategic revamp to control debtors and shift from direct hospital billing to a stockist model for Sparsh and Critical Care segments, which had previously affected working capital.

Indore Plant Ramp-up and Regulatory Milestones

The Indore plant's ramp-up is progressing in a step-wise, compliance-first manner. Output from Indore has increased from an average of INR 25-26 crores to INR 38-42 crores, with a target to reach INR 40-42 crores. The EU audit for the Indore facility was completed in December 2025, and the certificate is expected by March or April 2026. This approval is crucial for enabling an uplift in EU market revenues from Indore, anticipated by Q2 or Q3 FY27.

International Business and Botulinum Toxin Growth

The international business, particularly formulations exports, is showing strong growth, increasing by approximately INR 60-70 crores from a base of INR 120 crores. The Botulinum Toxin segment, branded Stunnox, has achieved a 23% market share in India, with revenues of INR 25-30 crores, and is growing at 20-25%. The company is also building capability for a broader aesthetic platform, including the upcoming launch of a fillers product by June-July 2026 through an agreement with a Canadian company, which is expected to further boost market share.

Domestic Branded Portfolio and Women's Health

Within the domestic branded portfolio, the focus remains on protocol-led depth and science-backed differentiation. Critical Care is concentrating on sepsis and resistant infections, while Sparsh is building differentiation through formats like dual chamber bags and plans to launch contrast media and total parenteral nutrition. The Women's Health platform, with brands like Guficin Alpha and Puregraf, continues to compound well, with the Ferticare segment growing 16-17%. The pipeline for women's health includes therapy tools for endometriosis, PCOS, and menopause.

Long-term Growth and Margin Outlook

Management targets a minimum of 15% revenue growth for FY27. In the long term, as Indore's capacity utilization rises above 50% (expected after 2-3 years), EBITDA margins are projected to improve from the current 16% to 19%. If utilization reaches over 75%, margins could further expand to 20-21%. The company aims to maintain its current debt level of INR 375 crores until March 2027 and reduce average receivable days from 140 to 120 in FY26.

Pipeline and Strategic Initiatives

Gufic is progressing with advanced molecules like Thymosin Alpha-1 (Immunocin-Alpha), Dalbavancin (Dalbavan), and Isavuconazole (Isavufic) for critical care. The company is also building a high lifetime value franchise in the Toxin Platform through injector creation and clinical data generation. The Nutra and Ayurveda platform is sharpening its focus on chronic care, with products like upgraded Gufican Oil and Vonoprazan (Vonpha). The long-term cancer vaccine project, Selvax, is still 5-6 years away from commercialization.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls